Monday morning kicks off one of the largest biotech events of the year: the JP Morgan Healthcare Conference. This conference is a four day event of the "who's who" in the world of biotech. Here, … [Read more...] about Big Week for Bio: JP Morgan Healthcare Conference
I previously posed an investment thesis for Seattle Genetics (SGEN) published here at MS Money Moves on May 24th, when the share price was $69.11. Seattle Genetics closed trading on December 24th at … [Read more...] about Seattle Genetics: Initial Expectations for Enfortumab Vedotin
Hello there, MS Chief Pharmaceutical Officer Chris here. I am elated to share something we have been working diligently on: an objective score to help evaluate biotechnology company. As the first of … [Read more...] about Exclusive New Feature: MS Biotech Financial Health Score
As we forge forward through the second half of 2019, many of the catalysts that once seemed over the horizon draw nearer. Here is my list of notable readouts from companies that I follow and/or are on … [Read more...] about My End of 2019 Notable Readouts
Sesen Bio (SESN) is down over 50% from its early summer highs, but the company is moving toward an inflection point. As disclosed earlier this year, Sesen has had several productive meetings with the … [Read more...] about Sesen Bio: The Accelerated Approval Misunderstanding
The previous earnings report from Verastem (VSTM) was filled with volatility and surprises. As I outlined in my last piece, Verastem's Earnings - Is It a Buy Now?, Verastem is a company filled with … [Read more...] about Another Quarter of Growth for Verastem…Is It Enough?
Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Tumor-agnostic therapy is the idea that a molecular or genetic alteration in a tumor can be targeted by a therapy, regardless of the tumors location in the body (link). This requires that the tumor be … [Read more...] about Tumor-Agnostic Therapy: LOXO…Array…Now Who?
Here is a brief summary of recent, yet important developments for Calithera (CALA), TG Therapeutics (TGTX) and Array Biopharma (ARRY) that may impact your investments and trades. Calithera On … [Read more...] about INVESTOR ALERT: Calithera, TG Therapeutics, and Array Biopharma